How to buy Enzo Biochem stock | $3.31

Enzo Biochem Inc is a diagnostics & research business based in the US. Enzo Biochem shares (ENZ) are listed on the NYSE and all prices are listed in US Dollars.

Enzo Biochem stock price (NYSE: ENZ)

Use our graph to track the performance of ENZ stocks over time.

Enzo Biochem shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$3.31
52-week range	$1.80 - $4.15
50-day moving average	$3.64
200-day moving average	$3.28
Wall St. target price	$5.50
PE ratio	140
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.03

Buy Enzo Biochem shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Enzo Biochem stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enzo Biochem price performance over time

Historical closes compared with the close of $3.31 from 2021-10-22

1 week (2021-10-15)	-12.43%
1 month (2021-09-23)	-8.56%
3 months (2021-07-23)	5.75%
6 months (2021-04-23)	1.53%

1 year (2020-10-23)	57.62%
2 years (2019-10-23)	3.44%
3 years (2018-10-23)	3.36
5 years (2016-10-21)	5.93

Is Enzo Biochem under- or over-valued?

Valuing Enzo Biochem stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enzo Biochem's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enzo Biochem's P/E ratio

Enzo Biochem's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 140x. In other words, Enzo Biochem shares trade at around 140x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Enzo Biochem's EBITDA

Enzo Biochem's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.4 million.

The EBITDA is a measure of a Enzo Biochem's overall financial performance and is widely used to measure a its profitability.

Enzo Biochem financials

Revenue TTM	$112.4 million
Gross profit TTM	$23.8 million
Return on assets TTM	-0.09%
Return on equity TTM	2.01%
Profit margin	1.14%
Book value	$1.34
Market capitalisation	$183.2 million

TTM: trailing 12 months

Shorting Enzo Biochem shares

There are currently 623,668 Enzo Biochem shares held short by investors – that's known as Enzo Biochem's "short interest". This figure is 6% up from 588,216 last month.

There are a few different ways that this level of interest in shorting Enzo Biochem shares can be evaluated.

Enzo Biochem's "short interest ratio" (SIR)

Enzo Biochem's "short interest ratio" (SIR) is the quantity of Enzo Biochem shares currently shorted divided by the average quantity of Enzo Biochem shares traded daily (recently around 79651.085568327). Enzo Biochem's SIR currently stands at 7.83. In other words for every 100,000 Enzo Biochem shares traded daily on the market, roughly 7830 shares are currently held short.

However Enzo Biochem's short interest can also be evaluated against the total number of Enzo Biochem shares, or, against the total number of tradable Enzo Biochem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enzo Biochem's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Enzo Biochem shares in existence, roughly 10 shares are currently held short) or 0.0202% of the tradable shares (for every 100,000 tradable Enzo Biochem shares, roughly 20 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Enzo Biochem.

Find out more about how you can short Enzo Biochem stock.

Enzo Biochem share dividends

We're not expecting Enzo Biochem to pay a dividend over the next 12 months.

Have Enzo Biochem's shares ever split?

Enzo Biochem's shares were split on a 105:100 basis on 20 October 2004. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your Enzo Biochem shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Enzo Biochem shares which in turn could have impacted Enzo Biochem's share price.

Enzo Biochem share price volatility

Over the last 12 months, Enzo Biochem's shares have ranged in value from as little as $1.8 up to $4.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Enzo Biochem's is 0.8418. This would suggest that Enzo Biochem's shares are less volatile than average (for this exchange).

Enzo Biochem overview

Enzo Biochem, Inc. , an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition.

Frequently asked questions

What percentage of Enzo Biochem is owned by insiders or institutions?
Currently 19.698% of Enzo Biochem shares are held by insiders and 50.007% by institutions. When does the fiscal year end for Enzo Biochem?
Enzo Biochem's fiscal year ends in July. Where is Enzo Biochem based?
Enzo Biochem's address is: 527 Madison Avenue, New York, NY, United States, 10022 What is Enzo Biochem's ISIN number?
Enzo Biochem's international securities identification number is: US2941001024 What is Enzo Biochem's CUSIP number?
Enzo Biochem's Committee on Uniform Securities Identification Procedures number is: 294100102